Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia-Reference-Cited by-同舟云学术

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia

Published:2017-09-18 Issue:4 Volume:59 Page:1008-1011
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Andritsos Leslie A.¹,Grieselhuber Nicole R.¹,Anghelina Mirela¹,Rogers Kerry A.¹,Roychowdhury Sameek²,Reeser Julie W.²,Timmers Cynthia D.²,Freud Aharon G.³,Blachly James S.¹,Lucas David M.¹,Lozanski Gerard³,Jones Jeffrey A.¹,Williams Katie¹,Oakes Christopher¹,Jones Dan³,Grever Michael R.¹

Affiliation:

1. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

2. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

3. Department of Pathology, The Ohio State University, Columbus, OH, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1365853

Reference17 articles.

1. Management of hairy cell leukemia variant